Current Report Filing (8-k)
January 26 2021 - 9:18AM
Edgar (US Regulatory)
0000887247
false
0000887247
2021-01-26
2021-01-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 26, 2021
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
11682 El Camino Real, Suite 300
San Diego, CA
|
|
92130
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (858) 997-2400
(Former name or Former Address, if Changed
Since Last Report.)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock
|
|
ADMP
|
|
NASDAQ
Capital Market
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
On January 26, 2021, Adamis Pharmaceuticals
Corporation (“Adamis” or the “Company”) issued a press release announcing that it has entered into a non-binding
letter of intent with a potential buyer for sale of substantially all of the assets of its US Compounding Inc. subsidiary. A copy
of the Company’s press release is attached hereto as Exhibit 99.1 is incorporated into this item by reference.
Forward Looking Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995 that are subject to a number of risks and uncertainties. These statements relate to future events our future results of
operations, including without limitation: whether Adamis and USC will negotiate any definitive agreements regarding the sale of
USC’s business and assets, the terms of any such definitive agreement, the timing of completion of any such transaction,
and the amount of gross consideration that Adamis and USC may receive at the closing of any such transaction or pursuant to the
promissory note or potential future contingent milestone payments contemplated by the letter of intent or any definitive agreement.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they
are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurances
that Adamis or USC will enter into any definitive agreements for the sale of the business and assets of USC or that, if such an
agreement is entered into, it will be completed, or concerning the time when the proposed transaction contemplated by the letter
of intent might be completed. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’
filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2019,
and our subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available
free of charge on the SEC's web site at http://www.sec.gov.
Except to the extent required by law, any forward-looking statements in this Report speak only as the date of this Report, and
Adamis expressly disclaims any obligation to update any forward-looking statements.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
Dated: January 26, 2021
|
By:
|
/s/ Robert O. Hopkins
|
|
Name:
|
Robert O. Hopkins
|
|
Title:
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024